中国人群载脂蛋白A5与动脉粥样硬化性心脑血管疾病  

Apolipoprotein A5 in atherosclerotic cardio-cerebrovascular diseases in the Chinese population

作　　者：查艺闻 梁景岩 ZHA Yiwen;LIANG Jingyan(Medical College,Yangzhou University,Yangzhou,Jiangsu,225001.China;Institute of Translational Medicine,Medical College,Yangzhou University;Jiangsu Key Laboratory of In-tegrated T raditional Chinese and W estern Medicine for Prevention and T reatment of Senile Dis-eases,Yangzhou University)

机构地区：[1]扬州大学医学院,江苏扬州225001 [2]扬州大学转化医学研究院 [3]扬州大学江苏省中西医结合老年病防治重点实验室

出　　处：《临床心血管病杂志》2020年第10期965-969,共5页Journal of Clinical Cardiology

基　　金：国家重点研发计划(No:2016YFE0126000);江苏省“六大人才高峰”高层次人才项目(No:2018WSN-082)。

摘　　要：载脂蛋白A5作为载脂蛋白家族的新成员,对血浆甘油三酯调节显著,其功能的缺失或障碍在动脉粥样硬化进程中发挥着不可忽视的作用,载脂蛋白A5基因的多态性在不同种族和地区对动脉粥样硬化性心脑血管疾病的影响存在差异。本文就载脂蛋白A5的结构、功能、机制以及近几年来有中国人群特异性的基因变异作一综述。Apolipoprotein A5,a novel member in the apolipoprotein family,plays an important role in regulating plasma triglycerides.Its dysfunction is associated with the progression of atherosclerosis.Its gene polymorphisms show different influence on the atherosclerotic cardio-cerebrovascular diseases within different regions and races.This review focuses on the structure,function,mechanism,and gene polymorphisms of apolipoprotein A5,particularly in the Chinese population in recent years.

关 键 词：载脂蛋白 甘油三酯 动脉粥样硬化 心血管疾病 脑血管疾病 

分 类 号：R541.4[医药卫生—心血管疾病]